Skip to main content
Journal of Peking University (Health Sciences) logoLink to Journal of Peking University (Health Sciences)
. 2020 Oct 19;52(6):1146–1149. [Article in Chinese] doi: 10.19723/j.issn.1671-167X.2020.06.027

白塞综合征合并急性格林巴利综合征1例

Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report

Chen YU 1, Chun LI 2, Yang-yi FAN 3, Yan XU 3,*
PMCID: PMC7745265  PMID: 33331329

Abstract

A 40-year-old male patient was referred to our department with complains of recurrent oral ulcer for more than 20 years and vulvar ulcer for more than 10 years. He presented with a 3-month history of right external ophthalmoplegia. More than 10 days ago, the patient received ganglioside infusion. And one week ago, he developed numbness and pain of his lambs, and progressive myasthenia, accompanied by right blepharoptosis and dysuria. On exam, motor strength was graded 0/5 in the lower and the upper extremities. Deep tendon reflexes were diminished in extremities. His admission medical examination: hemoglobin (HGB), white cell and platelet counts were normal. C-reactive protein (CRP) was negative. Erythrocyte sedimentation rate (ESR) 53 mm/h. Antinuclear antibody (ANA), anti-dsDNA antibody, anti-Smith antibody, anti-cardiolipin antibody and human leucocyte antigen B51 were all within normal range. The etiological tests of influenza A pathogen, influenza B pathogen, parainfluenza virus, enterovirus and parvovirus were all negative. He tested positive for serum anti-GM1 IgG. Cerebrospinal fluid had a normal white cell count, an elevated protein content. Gram staining, culture and PCR detection for varicella-zoster virus, cytomegalovirus and herpes simplex virus were all negative. Antibodies associated with autoimmune encephalitis and paraneoplastic syndrome were negative in cerebrospinal fluid. Electromyography and nerve conduction studies showed a severe axonal damage affecting motor nerves. No obvious abnormalities were observed in his magnetic resonance imaging of brain and cavernous sinus. The patient was diagnosed with Behcet syndrome complicated with acute Guillain-Barré syndrome. He received intravenous methylprednisolone, intravenous immunoglobulin (IVIg) therapy, plasma exchange and rituximab treatment. After treatment, the patient's muscle strength of limbs was restored to grade 1, blepharoptosis and pain disappeared. The nervous system involvement of Behcet syndrome is relatively rare, especially combined with Guillain-Barré syndrome, which is easy to cause misdiagnosis. The treatment of Behcet syndrome complicated with acute Guillain-Barré syndrome includes the treatment of primary disease, plasma exchange and IVIg therapy. In addition, supportive treatment is very important for such patients. The focus of treatment is to avoid respiratory insufficiency, prevent deep vein thrombosis, monitor cardiac function and hemodynamics. Pain-relieving, physical exercise and psychological support are often under-recognized. The rehabilitation treatment is very important to improve the prognosis and quality of life of patients. What we need to learn is that when the symptoms and signs of the nervous system are difficult to be explained by neuro-Behcet syndrome alone, we should be alert to the possibility of other nervous system diseases.

Keywords: Behcet syndrome; Guillain-Barré syndrome; Case reports; Immunoglobulins, intravenous


白塞综合征(Behcet syndrome, BS)是一种复杂的多系统疾病,临床特征为口腔溃疡、生殖器溃疡、皮肤病变,以及眼、神经等受累。中东和地中海地区的BS患病率高、病情重,因此该病又称“丝绸之路病”。BS属于罕见病的一种,而急性格林巴利综合征同样也属于罕见病。本文报道1例BS合并急性格林巴利综合征的患者,结合以往文献复习,以期进一步提高临床对两种罕见疾病的认识。

1. 病历资料

患者男性,40岁,主因“反复口腔溃疡20余年,外阴溃疡10余年,四肢乏力1周”收入北京大学人民医院风湿免疫科治疗。患者20余年前无明显诱因出现反复口腔溃疡,1~2次/月,每次2~4个痛性溃疡,食用水果等富含维生素食物无明显好转,每次持续约1周;10余年前开始无明显诱因出现外阴溃疡,每次2~3个,每次发作2~3天,每年发作4~5次;上述溃疡均未诊治。3个多月前出现右侧眼眶肿痛及右眼单眼视物成双,持续约1周后自行缓解,1个多月前再次出现右侧眼眶肿痛及右眼单眼视物成双,于外院就诊检查脑脊液压力、常规、生化、病原学、自身免疫性脑炎、副肿瘤综合征相关抗体均未见明显异常,诊断为“眼外直肌麻痹、白塞综合征”,入本院前2周曾接受神经节苷脂40 mg/d静脉滴注,共7天。入院前1周,患者突发四肢远端麻木、疼痛,进行性四肢肌力减退,右侧眼睑下垂,入院前6天出现排便无力,入院前5天出现下肢乏力加重,难以站立,双手不能持物,生活不能自理,故就诊于我院急诊科。诊断为BS、周围神经病变不除外,予患者甲泼尼龙琥珀酸钠(商品名:甲强龙)500 mg/d×3 d,后改为甲强龙80 mg/d×5 d,丙种球蛋白20 g/d×5 d治疗,患者四肢乏力症状仍持续加重,入院前1天出现四肢瘫痪,四肢近端及远端肌力0级,下肢疼痛明显,右眼睑下垂,无明显吞咽困难、呼吸困难、腹泻、意识丧失等表现。

患者入院后体格检查:血压128/84 mmHg,被动体位,右侧眼睑下垂,右眼瞳孔直径5 mm,左眼瞳孔直径约3 mm,右侧眼球运动减退,右眼内收幅度约2 mm,向其余方向运动不能,右眼直接及间接对光反射消失,左眼对光反射存在,其余颅神经征阴性,四肢肌力0级,肌张力低,生理反射减弱,病理反射未引出,痛觉对称灵敏存在,脑膜刺激征阴性。

患者入院后实验室辅助检查:血常规正常,红细胞沉降率53 mm/h,C反应蛋白正常,白介素6为21.24 ng/L,抗核抗体、抗可溶性抗原(extractable nuclear antigen,ENA)抗体、抗双链DNA(double-stranded DNA,dsDNA)抗体、抗中性粒细胞胞浆抗体(anti-neutrophil cytoplasmic antibodies,ANCA)及抗心磷脂抗体均为阴性,抗内皮细胞抗体(anti-endotheliocyte antibody,AECA)、人类白细胞抗原(human leukocyte antigen,HLA)-B51阴性。感染相关化验显示,降钙素原、巨细胞病毒、EB病毒(Epstein-Barr virus, EBV)、甲型流感病原、乙型流感病原、副流感病毒、肠道病毒、细小病毒核酸检测均为阴性。血清神经节苷脂谱抗体(monosialotetrahexo sylganglioside, GM1) IgG阳性,四肢无力症状出现后第8天脑脊液总蛋白0.57 g/L(↑),脑脊液常规检查显示蛋白质定性(+),细胞数正常,寡克隆带阴性,脑脊液神经元特异性烯醇化酶27.98 μg/L,中枢神经特异性蛋白1.210 μg/L,脑脊液GM1抗体阴性,脑脊液病原学、自身免疫性脑炎、副肿瘤综合征相关抗体阴性,头颅MRI平扫脑实质未见明显异常,海绵窦未见明显异常。肌电图检查提示四肢运动神经纤维轴索损害显著,感觉神经正常,所检查运动神经的复合肌肉动作电位(compound muscle action potential,CMAP)波幅均显著降低,双侧胫神经F波及H波均未明显诱出,其余神经的运动神经传导速度(motor nerve conduction velocity, MCV)和感觉神经传导速度(sensory nerve conduction velocity, SCV)在正常范围的低限水平,SCV和波幅均正常。入院诊断为BS合并急性格林巴利综合征(急性轴索性运动神经病)。

患者入院后给予甲强龙40 mg/d静脉滴注,5次血浆置换,血浆每次置换量2 000 mL,期间给予患者营养神经、补钙、抑酸等对症治疗,血浆置换5次后给予丙种球蛋白治疗,利妥昔单抗500 mg(D1、D15,D:day)静脉滴注,第1次输入利妥昔单抗后患者右侧眼睑用力时可部分上抬,四肢麻木及疼痛症状减轻,但四肢肌力仍为0级,第2次输入利妥昔单抗后,右侧眼睑可上抬,四肢肌力恢复至1级。患者症状平稳后出院至康复医院行康复治疗。

2. 分析与讨论

该患者为中年男性,慢性病程急性加重,既往反复口腔溃疡病史且发作频率每年3次以上,反复外阴溃疡,符合2014年修订的《国际白塞综合征诊断标准》,得分为4分,BS诊断明确。神经白塞综合征(neuro-Behcet syndrome,NBS)是指BS患者的神经系统症状和/或体征的组合,其在BS患者中的发生率约为9%(3%~30%)[1]。NBS目前尚无独立的诊断标准,当满足BS诊断标准的同时,伴有神经系统受累的症状和体征时应考虑NBS[2]。NBS可分为实质性NBS和非实质性NBS,实质性NBS主要表现为脑膜脑炎(约占实质性NBS的75%)[2],大脑半球、脑干、脊髓等受累,非实质性NBS也称为血管性NBS,主要表现为大脑静脉窦血栓形成、颅内动脉瘤或夹层等血管病变。BS的周围神经系统受累较为少见(约0.8%),可表现为周围神经病变、多发性单神经炎、肌病和肌炎等。头颅MRI对NBS与其他神经系统疾病的鉴别具有重要意义。NBS的治疗以糖皮质激素为主,对于症状严重或复发患者可考虑联合硫唑嘌呤治疗,必要时应使用更有效的免疫抑制药物,如霉酚酸酯、甲氨蝶呤、环磷酰胺或靶向治疗。环孢素可能与BS的神经系统并发症相关,故有NBS病史的患者应尽量避免使用[3]。近年来,生物制剂在难治性NBS中的使用有所增加,使用较多的包括肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)抑制剂、干扰素α(interferon-α,INF-α)等。

NBS累及脑干时可出现眼压增高、颅神经麻痹的临床症状。本例患者神经受累首发症状为右眼单眼视物成双及右侧眼睑下垂,伴有右眼瞳孔对光反射及眼球运动异常,考虑眼外肌麻痹。既往有文献报道,上睑下垂和(或)双眼复视是眼外肌麻痹的常见表现,单侧眼外肌麻痹病变多为眼球运动神经病变,可由重症肌无力、格林巴利综合征、缺血性眼球运动神经损害、局部非特异性炎症等各种病因引起[4],因此本例患者的颅神经受累仍不能除外实质性NBS所致。患者随后出现四肢对称性肌无力,体格检查显示腱反射减弱,头颅MRI未见明显异常,脑脊液提示蛋白-细胞分离,肌电图提示运动神经轴索损害。为除外合并其他神经系统疾病,进一步送检脑脊液及外周血神经节苷脂谱抗体检查,提示外周血抗GM1 IgG阳性,该抗体阳性无法用NBS解释,结合患者症状、体征及辅助检查,考虑患者诊断为BS合并格林巴利综合征。

既往文献报道,BS可合并格林巴利综合征,但相对较少见[5]。自身免疫疾病合并格林巴利综合征者也较为罕见,国内外曾有系统性红斑狼疮合并格林巴利综合征的个案报道,其发病机制尚不明确,细胞免疫和体液免疫可能在其中发挥作用[6]。格林巴利综合征是一种最常见的急性炎症性脱髓鞘性神经病变,以四肢对称性肌无力、反射减退或消失为特征[7],发病率为0.81~1.89(中位数为1.1)/10万人年[8],其发生常有前驱感染史或疫苗接种史,空肠弯曲菌是前驱感染最常见的病原体,空肠弯曲菌的细菌脂寡糖与人类神经细胞膜上高表达的神经节苷脂之间存在分子模拟,前驱感染时可诱导机体产生抗神经节苷脂抗体,与神经细胞膜上的神经节苷脂发生交叉反应,由此导致补体介导的运动神经损伤[9]。格林巴利综合征最常见的亚型为急性炎性脱髓鞘多神经根神经病变和急性运动性轴索神经病(acute motor axonal neuropathy, AMAN),其次为Miller-Fisher综合征(Miller-Fisher syndrome,MFS)。AMAN是格林巴利综合征的纯运动神经轴突亚型,肢体无力迅速发展,感觉神经很少被累及,肌电图主要特征是CMAP波幅降低(< 80%正常下限),但2条或更多神经无脱髓鞘证据[10]。抗GM1 IgG是AMAN特征性生物标志物。根据本例患者临床表现及肌电图检查等结果,考虑患者为AMAN,但患者无前驱感染史,入院后多次病原学筛查均为阴性。尽管很罕见,但格林巴利综合征可能会在非感染性事件后发生,外源性神经节苷脂便是其中的一种非感染性因素。本例患者曾于肌无力症状发作前1周有GM1输注史并在输液过程中出现了过敏反应,本研究对此进行了文献回顾。GM1是神经节苷脂的一个亚型,广泛应用于急性脑梗死、脑出血、颅脑损伤、周围神经病变等神经内外科疾病的治疗。既往曾有数例GM1相关性格林巴利综合征的报道,但较少见,主要类型为AMAN,且发病近期多有GM1静脉滴注史,可出现典型四肢弛缓性瘫痪,脑脊液可见蛋白-细胞分离现象,肌电图提示轴索损害,部分患者血清及脑脊液中抗神经节苷脂抗体抗GM1阳性[11-12],结合本例患者的用药史及病例特点,目前不除外神经节苷脂引起的格林巴利综合征。目前关于外源性神经节苷脂和格林巴利综合征之间的关系仍然存在争议[13],且神经节苷脂治疗后格林巴利综合征的发病机制尚不完全清楚,有研究推测可能与空肠弯曲杆菌相关格林巴利综合征具有相同的发病机制[14]。纯度较低的神经节苷脂可能通过“分子模拟”改变个体的易感性而引发格林巴利综合征。国内有回顾性研究报道了12例应用神经节苷脂治疗格林巴利综合征患者,这些患者与近期的创伤、手术、急性脑血管疾病或慢性周围神经病变有关[15]。格林巴利综合征是一种免疫介导性疾病,因各种疾病导致的免疫功能改变可能在格林巴利综合征发病机制中发挥协同作用。意大利卫生局禁止将神经节苷脂用于各种自身免疫性疾病。本例患者在使用神经节苷脂治疗前已经出现眼外肌麻痹症状,而四肢对称性弛缓性瘫痪发生在其后,值得注意的是,格林巴利综合征的AMAN亚型颅神经受累较为罕见,MFS亚型也可表现为眼肌麻痹,但其多为双眼对称性眼肌麻痹,此类患者神经传导检查多数正常,可出现感觉神经传导分离性改变,MFS患者的自身抗体多以GQ1b和GT1a为主[7],与本例患者的检验结果不符。目前尚不能完全明确本例患者的AMAN是由NBS或是应用神经节苷脂所致,或两者均参与了起病过程,具体病理机制有待进一步研究证实。

对于BS合并急性格林巴利综合征的治疗,主要以原发病治疗、丙种球蛋白、血浆置换治疗为主,尤其对于快速进行性肌无力的患者,血浆置换与免疫球蛋白治疗关键且有效[7]。血浆置换在发病2周内开始治疗效果最佳,通常的治疗方案为2周之内血浆置换共5次,血浆置换总剂量为血浆量的5倍。丙种球蛋白对于发病2周内的患者也是有效的,常规方案为0.4 g/kg×5 d。近些年,生物制剂在格林巴利综合征中的应用也得到了广泛关注,以往文献报道,利妥昔单抗在神经肌肉疾病中显示出较好的疗效和较低的副作用[16],尤其对于经糖皮质激素、丙种球蛋白、血浆置换治疗效果不佳的难治性神经肌肉疾病可有一定的疗效,但其证据仅限于个案报道,目前尚缺乏大型前瞻性随机对照试验进一步证实。有国外文献报道,利妥昔单抗在改善抗神经节苷脂类抗体相关格林巴利综合征的AMAN亚型中的治疗有效[17],国内尚未见使用利妥昔单抗治疗格林巴利综合征疗效的报道。

格林巴利综合征患者的症状多在4周内达到高峰,随后的恢复期可能持续数月或数年。尽管部分患者在经丙种球蛋白或血浆置换后可很快恢复,但约20%的患者在发病后6个月肌力仍无法恢复,因此后期的康复治疗对于患者的预后和生活质量很重要[7, 18]。本例患者采用甲强龙500 mg/d×5 d后改为40 mg/d治疗NBS,采用血浆置换5次、丙种球蛋白及利妥昔单抗治疗格林巴利综合征后,患者右眼睑可上抬、四肢肌力恢复至1级,治疗结束后至康复医院进一步治疗。

综上所述,BS神经系统受累相对少见,而合并格林巴利综合征则鲜有报道,其发生机制及前驱因素目前尚未明了,原发病的治疗、血浆置换及丙种球蛋白输注是目前主要的治疗手段。该病例给我们的警示是,当神经系统症状及体征难以单独用NBS解释时,需警惕合并其他神经系统疾病的可能性。

References

  • 1.Borhani-Haghighi A, Kardeh B, Banerjee S, et al. Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. Mult Scler Relat Disord. 2019;39:101906. doi: 10.1016/j.msard.2019.101906. [DOI] [PubMed] [Google Scholar]
  • 2.Al-Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204. doi: 10.1016/S1474-4422(09)70015-8. [DOI] [PubMed] [Google Scholar]
  • 3.Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. J Neurol. 2014;261(9):1662–1676. doi: 10.1007/s00415-013-7209-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.雷 涛, 李 正仪, 刘 轩, et al. 眼外肌麻痹患者257例的临床特征及病因分析. 中华临床医师杂志:电子版. 2013;7(23):128–131. [Google Scholar]
  • 5.Shugaiv E, Kiyat-Atamer A, Tüzün E, et al. Coexistence of Guillain-Barré syndrome and Behçet's disease. Clin Exp Rheumatol. 2013;31(3 Suppl 77):88–89. [PubMed] [Google Scholar]
  • 6.Nadri Q, Althaf MM. Guillian-Barré syndrome as the initial presentation of systemic lupus erythematosus: case report and review of literature. Ann Saudi Med. 2015;35(3):263–265. doi: 10.5144/0256-4947.2015.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717–727. doi: 10.1016/S0140-6736(16)00339-1. [DOI] [PubMed] [Google Scholar]
  • 8.Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123–133. doi: 10.1159/000324710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Yanaka S, Yogo R, Watanabe H, et al. On-membrane dynamic interplay between anti-GM1 IgG antibodies and complement component C1q. Int J Mol Sci. 2019;21(1):147. doi: 10.3390/ijms21010147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin Neurophysiol. 2012;123(8):1487–1495. doi: 10.1016/j.clinph.2012.01.025. [DOI] [PubMed] [Google Scholar]
  • 11.雷 海波, 龙 靓, 李 荣辉, et al. 静脉注射神经节苷脂致格林巴利综合征文献的回顾分析. 中国临床药学杂志. 2016;25(4):233–236. [Google Scholar]
  • 12.罗 少成, 周 玉兰, 王 欣. 神经节苷脂相关性格林-巴利综合征的研究进展. 中国城乡企业卫生. 2019;34(7):73–75. [Google Scholar]
  • 13.Govoni V, Granieri E, Manconi M, et al. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy. J Neurol Sci. 2003;216(1):99–103. doi: 10.1016/s0022-510x(03)00215-6. [DOI] [PubMed] [Google Scholar]
  • 14.Kusunoki S, Kaida K, Ueda M. Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research. Biochim Biophys Acta. 2008;1780(3):441–444. doi: 10.1016/j.bbagen.2007.10.001. [DOI] [PubMed] [Google Scholar]
  • 15.Zhang L, Fang Y, Cheng X, et al. Curcumin exerts effects on the pathophysiology of Alzheimer's disease by regulating PI(3, 5)P2 and transient receptor potential mucolipin-1 expression. Front Neurol. 2017;8:531. doi: 10.3389/fneur.2017.00531. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 16.Maclsaac J, Siddiqui R, Jamula E, et al. Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin. Transfusion. 2018;58(11):2729–2735. doi: 10.1111/trf.14841. [DOI] [PubMed] [Google Scholar]
  • 17.Motamed-Gorji N, Matin N, Tabatabaie O, et al. Biological drugs in Guillain-Barré syndrome: An update. Curr Neuropharmacol. 2017;15(7):938–950. doi: 10.2174/1570159X14666161213114904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–482. doi: 10.1038/nrneurol.2014.121. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Peking University (Health Sciences) are provided here courtesy of Editorial Office of Beijing Da Xue Xue Bao Yi Xue Ban, Peking University Health Science Center

RESOURCES